PHAR - Pharming Group N.V. Enterprise Value
Commercial solutions from Pharming Group N.V. (PHAR) for combating rare immune pathologies are growing actively, as confirmed by the price action on the GURU.Markets platform, where the metric stands at 808.63. The business relies on the orphan drug segment, leading in the therapy of hereditary angioedema via Ruconest and gene technologies. High authority among physicians and patients in Europe solidifies its status as a reliable supplier of life-saving medications.
Pharming Group N.V. (PHAR) - metric breakdowns and financial figures
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Comprehensive company analysis:Pharming Group NV (PHAR)
The enterprise value of Pharming Group N.V. (PHAR) reflects the total cost of acquiring the business within the orphan drug sector. This metric aggregates market capitalization and debt obligations, minus existing cash reserves. By analyzing the market valuation of assets excluding liquidity, an investor sees the real value of all operational resources. Stable demand for rare medicines ensures predictable flows, smoothing the dynamics of this indicator. Such resilience minimizes the risks of a sharp revaluation of the company.
Competitor analysis for Pharming Group N.V.
Value Adjusted for Debt and Cash argenx N.V. ARGX|BioNTech Group - Enterprise Value|ABVX: Enterprise Value|Total Company Value ADMA Biologics ADMA|PTGX (protagonist-inc.com) - Value Adjusted for Debt and Cash|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value BioCryst Pharmaceuticals (BCRX)|VERA: Value Adjusted for Debt and Cash|DNTH (Dianthus Pharma) - Total Company Value|Pharvaris Pharma (PHVS) - Real Price to Acquire Entire Company|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com (TRML)|Precigen (PGEN) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Nektar Therapeutics Inc (NKTR)|Enterprise Value UPB|Zenas Corp - Company Buyout Price|IMNM: Total Company Value|GOSS: Real Price to Acquire Entire Company|KALV (KalVista Pharmaceuticals, Inc.) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Real Price to Acquire Entire Company|Enterprise Value SVRA|Total Company Value Rigel Pharmaceuticals RIGL|Business Value anaptysbio.com (ANAB)|ATXS: Enterprise Value|enGene Holdings Inc - Total Enterprise Value|Total Company Value RAPT Therapeutics|JBIO - Full Business Value|Enterprise Value Aclaris Therapeutics ACRS|kyvernatx.com (KYTX) - Value Adjusted for Debt and Cash|TLSA (Tiziana Life Sciences Ltd) - Enterprise Value|Enterprise Value CABA|Ventyx Bio (VTYX) - Total Company Value|Value Adjusted for Debt and Cash THTX (Theratechnologies, Inc)|Avalo Therapeutics, Inc - Total Company Value|Real Price to Acquire Entire Company eledon.com ELDN|Enterprise Value AGEN (Agenus Inc.)|CLYM: Company Buyout Price|Total Company Value Zura Bio|aTyr Pharmaceuticals (ATYR) - Business Value|Adagene Inc - Enterprise Value|Full Takeover Company Value Ikena Oncology, Inc. (IMA)|Shattuck Labs, Inc. (STTK) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash equilliumbio.com (EQ)|CNTB (Connect Biopharma Holdings Limited) - Enterprise Value|Immunic Therapeutics - Full Takeover Company Value|Total Company Value Atara Biotherapeutics Inc (ATRA)|IFRX: Value Adjusted for Debt and Cash|Total Company Value XFOR|Total Enterprise Value Adicet Bio, Inc.|CELU (Celularity Inc) - Real Price to Acquire Entire Company|Enterprise Value INMB|BRNS - Total Company Value|Full Business Value kezarlifesciences.com KZR|Real Price to Acquire Entire Company SAB Biotherapeutics, Inc.|Akari Therapeutics PLC - Value Adjusted for Debt and Cash|Enlivex Therapeutics, Ltd. (ENLV) - Total Company Value|Q32 Bio Inc. (QTTB) - Business Value|GeoVax Labs, Inc. - Real Price to Acquire Entire Company|Company Buyout Price edesabiotech.com|Real Price to Acquire Entire Company iBio|Total Company Value Carisma Tx (CARM)|XTLB (XTL Biopharmaceuticals, Ltd.) - Real Price to Acquire Entire Company|Company Buyout Price BOLT (boltbio.com)|HCW Biologics (HCWB) - Total Company Value|Full Business Value Aptevo Therapeutics, Inc. APVO|Enterprise Value AIM ImmunoTech Inc. (AIM)|ADTX - Value Adjusted for Debt and Cash|GRI: Enterprise Value|XRTX (XORTX Corp) - Enterprise Value|HIND - Total Company Value|Value Adjusted for Debt and Cash REVB|INDP - Total Company Value|Full Business Value Scinai Immunotherapeutics Ltd (SCNI)|Enterprise Value CalciMedica|Value Adjusted for Debt and Cash Affimed NV AFMD|Allakos Therapeutics - Enterprise Value|HOOK: Enterprise Value|Total Company Value igmbio.com IGMS|ITOS (iTeos Therapeutics Inc) - Value Adjusted for Debt and Cash|Total Company Value OCEA|Real Price to Acquire Entire Company TC BioPharm Ltd|Enterprise Value THRD